Recurium IP Holdings, LLC

Zeno Royalties & Milestones, LLC

Chad Daniel Hopkins

Kevin Duane Bunker

Joseph Robert Pinchman

Peter Qinhua Huang

Deborah Helen Slee

Mehmet Kahraman

Sunny Abraham

Rakesh Kumar Sit

Sayee Gajanan Hegde

Brant Clayton Boren

Daniel Lee Severance

Chuangxing Guo

Mark Charles Grier

Sunil Paliwal

Hui Liu

Aditya Krishnan Unni

Qinhua Huang

Disclosed herein are nitrogen-containing bicyclic compounds of Formula (I), including pharmaceutically acceptable salts thereof, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

EGFR inhibitor compounds

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones

Disclosed herein are compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), methods of synthesizing compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It), and methods of using compounds of Formulae (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ik), (Im), (In), (Io), (Ip), (Iq), (Ir), (Is) and (It) as an analgesic.

Analgesic compounds

Disclosed herein are nitrogen-containing bicyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

Compounds of Formula (I) are estrogen receptor alpha modulators, where the variables in Formula (I) are described in the disclosure. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions that are estrogen receptor alpha dependent and/or estrogen receptor alpha mediated, including conditions characterized by excessive cellular proliferation, such as breast cancer. 

Estrogen receptor modulators

Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.

Bicyclic compounds

Methods of preparing substituted bicyclo[0.1.1.1]pentane compounds of Formula (I) comprise reacting a compound of Formula (A) with a compound of Formula (B) in the presence of a first transition metal catalyst selected from a palladium catalyst and a nickel catalyst, where the variables R, R, Xand Xare as described herein.

Methods for cross coupling

Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.

Disclosed herein are spirocyclic compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.

Growing community of inventors

San Diego, CA, United States of America

Chad Daniel Hopkins